SLSai Life Sciences544306Routine director change

Board approves SMP appointments, Q2/H1 results and ESOP share allotment

Board approved Siddhartha Das (SVP & Head-HR), Vijay Kumar Suthari (VP-Head Quality & Regulatory Affairs) and Sriram Gopalakrishnan (SVP-Corporate Communications) as SMPs from 05 Nov 2026.

By ScoutQuest · Thu 5 Nov 2026, 11:06 PM IST · 3 min read

ESOP/MESOP shares allotted

27,005 under ESOP 2008 and 81,000 under MESOP 2018, total 1,08,005 shares, face value Rs. 1 each

Total issued shares after allotment

21,25,80,721

Q2/H1 standalone revenue and profit

Revenue from operations 6,470.82; profit for the period 960.13 (Rs. million)

New senior management appointments

At its meeting held on 05 November 2026, the Board of Directors approved the appointment of Mr. Siddhartha Das, Mr. Vijay Kumar Suthari and Mr. Sriram Gopalakrishnan as Senior Management Personnel (SMP) of the company with effect from 05 November 2026. The appointments were made on the recommendation of the Nomination and Remuneration Committee.

• Mr. Siddhartha Das: Senior Vice President & Head - Human Resources. A human resources professional with experience across FMCG, pharmaceuticals, life sciences and infrastructure. He holds a Master's degree in Social Work and has completed an Executive MBA from XLRI, and has been associated with the company for the past two years.
• Mr. Vijay Kumar Suthari: Vice President - Head Quality & Regulatory Affairs. A pharmaceutical industry professional with experience in quality assurance, quality control, regulatory compliance, quality systems and operational excellence. He was previously associated with Dr. Reddy's Laboratories Limited, and earlier with Novartis India Limited, AMRI (Albany Molecular Research Inc.) and Pfizer India Limited. He holds a Bachelor of Pharmacy degree from Osmania University, Hyderabad.
• Mr. Sriram Gopalakrishnan: Senior Vice President - Corporate Communications. A marketing and communications professional with experience in brand strategy, corporate communications, stakeholder engagement and reputation management. He has been associated with the company since November 2018 and earlier held leadership roles at Dr. Reddy's Laboratories and the Indian School of Business, and worked with advertising agencies including Ogilvy, Lowe Worldwide and RK Swamy BBDO. He holds a Bachelor's degree in Commerce from the University of Delhi and a Post Graduate Programme in Management (PGP) from the Indian School of Business, Hyderabad.

The update marks each of these as an appointment, designated and classified as Senior Management Personnel (SMP).

Quarterly and half-yearly results approved

The same Board meeting approved the unaudited standalone and consolidated financial results of the company for the second quarter and half year ended 30 September 2026, together with the limited review reports on them. In the standalone statement of unaudited financial results, revenue from operations for the quarter ended 30 September 2026 is 6,470.82 and profit for the period is 960.13 (the statement is presented in Rs. million).

Shares allotted under employee stock option plans

• 27,005 equity shares allotted on exercise of options under the Employees Stock Option Plan 2008 (ESOP 2008) and 81,000 equity shares under the Management Employee Stock Option Plan 2018 (MESOP 2018), a total of 1,08,005 shares, all fully paid-up with a face value of Rs. 1 each.
• Consequent to the allotment, the issued, subscribed and paid-up equity share capital rose from ~₹21.25 crore to ~₹21.26 crore, and total issued shares after the allotment stand at 21,25,80,721.
• No lock-in applies to the allotted shares, and they are identical in all respects to the existing equity shares of the company.

What this means for retail investors

• These are senior management appointments. The update sets out the professional background of each appointee, covering the human resources, quality and regulatory, and corporate communications functions.
• The share allotment is an exercise of employee stock options: new shares are issued to option holders, which increases the number of shares in issue and the paid-up share capital by the face value of the shares allotted.
• The financial results approved at the same meeting cover the standalone and consolidated business for the quarter and half year ended 30 September 2026.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev